Cell Dissociation Market

The global cell dissociation market in terms of revenue was estimated to be worth $0.6 billion in 2023 and is poised to reach $1.4 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The new edition of the report provides updated financial information through 2022 (depending on availability) for each listed company in a graphical representation. This would help in the easy analysis of the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating region or country, and business segment focus in terms of the highest revenue-generating segment. Key driving factors of the market include an increase in demand for personalized medicine, cGMP approvals each year for new production facilities developing cell therapies, and the growing use of cell dissociation products in mammalian cell culture to develop recombinant therapeutics. Additionally, advancements in non-enzymatic dissociation approaches are expected to offer lucrative opportunities for the end users of this market. Expensive cell-based research is a major hindrance to the market growth.

To know about the assumptions considered for the study, download the pdf brochure

Cell dissociation Market Dynamics

Driver: Increase in recombinant therapeutics sourced from mammalian cells

The biopharmaceutical industry has witnessed a considerable increase in the proportion of recombinant therapeutics sourced from mammalian cells since 2002. The number of approved recombinant products from mammalian cell culture increased by 8.5% annually from 2002 to 2022. As of June 2022, more than 300 recombinant products have been commercialized, indicating a rapid shift towards mammalian-based therapeutics, which nearly account for 67% of therapeutics in 2022. .Cell culture products, including cell dissociation form an integral part of developing mammalian-based recombinant therapeutics, propelling the industry growth.

Restraint: High cost of cell-based research

Isolation and purification of cell organelles integrates expensive products, additionally, automated/sem-automated benchtop instruments are more expensive than traditional methods. Despite significant benefits offered by automated instruments, high costs associated with these instruments may limit the adoption of products further restraining the market growth.

Opportunity: Advancements in non-enzymatic tissue dissociation

Companies operating in the market are introducing innovative and advanced products to overcome competition and generate more revenue. Most researchers in R&D institutes and biotechnology companies have primarily relied on traditional enzymatic dissociation products to separate cells from primary tissues. Although these traditional enzymatic dissociation products have advantages, such as better dissociation while performing research, they can sometimes be cytotoxic and damage viable cells. To overcome this issue and differentiate their product offerings, several companies are introducing non-enzymatic products that are non-cytotoxic. Owing to this advantage, the demand for non-enzymatic dissociation products is increasing among several end users.

Challenge: Limitations associated with dissociated cell culture

The key limitation of dissociated cultures is the small number of cells relative to immortalized cell lines. This makes it difficult to perform biochemical experiments requiring a high starting material volume. Additionally, most primary cell cultures are not homogeneous, which poses a challenging scenario for cell dissociation experiments. Neuronal cultures are often mixtures of both glia and neurons that respond to different neurotransmitters, so identifying an individual population of cells can be difficult.

The enzymatic dissociation segment accounted for the largest share of the cell dissociation industry in 2022

Based on the product, the cell dissociation market is segmented into non-enzymatic dissociation products, enzymatic dissociation products and instruments & accessories. Collagenase segment is the key contributor to the dominance of enzymatic dissociation products. More than 20 different types of collagenases exist, but only a handful are most suited for the enzyme dissociation of tissues. These suitable collagenases can maximize the number of viable, dissociated cells. Collagenase type 1 is typically recommended for liver, epithelial, adrenal, and adipocyte tissue dissociation.

The connective tissue segment of the cell dissociation industry is expected to grow at the highest CAGR during the forecast period

By tissue type, the cell dissociation market is segmented cell detachment and tissue dissociation. The tissue dissociation segment accounted for the largest market share in 2022. Collagen fibers are present in varying concentrations in almost all connective tissues. Elastic fibers are less abundant than the collagen varieties, somewhat similar to reticular fibers, wherein they form branching networks in connective tissues.

Pharmaceutical and biotechnology companies are the dominant end user segment of the cell dissociation industry in 2022

Based on end-users, the cell dissociation market is segmented into pharmaceutical & biotechnology companies, research institutes & academic institutes, and other end users. Pharmaceutical & biotechnology companies utilize cell culture products, including cell dissociation products, to research various chronic diseases. Additionally, the R&D investments in these companies have been increasing over the last few years, which has contributed to the dominance of this segment.

Asia Pacific region is anticipated to grow at the fastest pace in the cell dissociation industry through the forecast period

Based on the region, the cell dissociation market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific region is anticipated to grow at the fastest pace in the market through the forecast period. APAC’s pharmaceutical markets remain highly competitive and extremely fragmented, with thousands of small manufacturers competing for market shares. From an economic and policy standpoint, government support is expected to drive innovation in life sciences research and the growth of the pharmaceutical and biopharmaceutical sector.

The prominent players in the global cell dissociation market are Merck KGaA (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Corning Incorporated (US), Becton, Dickinson and Company (US), STEMCELL Technologies (Canada), PromoCell GmbH (Germany), Miltenyi Biotec (Germany), ATCC (US), HiMedia Laboratories (India), PAN-Biotech (Germany), CellSystems GmbH (Germany), AMSBIO (England), Neuromics (US), VitaCyte, LLC. (US), ALSTEM (US), Biological Industries (Israel), Gemini Bio (US), Innovative Cell Technologies, Inc. (US), Central Drug House (P) Ltd. (India), Worthington Biochemical Corporation (US), Capricorn Scientific (Germany), Abeomics (US), and Genlantis, Inc. (US).

Scope of the Cell Dissociation Industry:

This research report categorizes the cell dissociation market to forecast revenue and analyze trends in each of the following submarkets

By Product

• Enzymatic Dissociation Products
  • Collagenase
  • Trypsin
  • Papain
  • Elastase
  • DNase
  • Hyaluronidase
  • Other Enzymes
• Non-Enzymatic Dissociation Agents
• Instruments & Accessories

By Tissue Type

• Connective Tissues
• Epithelial Tissues
• Other tissues

By Application

• Tissue dissociation
• Cell detachment

By End User

• Pharmaceutical and Biotechnology companies
• Research and Academics
• other end users

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • RoE
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
• Rest of the World

Recent Development of Cell Dissociation Industry

• In 2020, Miltenyi Biotec launched automated and closed adherent cell culture solutions on CliniMACS Prodigy.
• In 2020, Merck The company expanded its Life Sciences production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire (US).
• In 2020, STEMCELL Technologies partnered with CollPlant to secure CollPlant rhCollagen for STEMCELL’s use in cell culture applications.
• In 2021, Danaher (Cytiva) partnered with Diamyd Medical, wherein Diamyd selected Cytiva’s FlexFactory platform for making precision medicine type-1 diabetes vaccines.
• In 2021, Danaher (Cytiva) collaborated with the Government of Telangana (India) to strengthen the biopharma industry in India with new labs.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst